Description
This section will provide an overview and understanding of:
- Key stakeholders in the German retail & hospital market
- Pricing and Reimbursement timelines in Germany
- Opportunities for early Advice Meetings with G-BA
- Extra funding pathways for Orphan Drugs and the special Pricing and Reimbursement process dedicated to them
- Illustrative analogue cases showcasing HTA assessments by the G-BA and price outcomes for specific medicines and therapeutic areas
